Efficacy of intralesional betamethasone for erosive oral lichen planus and evaluation of recurrence: a randomized, controlled trial.
This study aimed to determine the efficacy and safety of intralesional betamethasone in erosive oral lichen planus and to evaluate relapse of erosion. Patients were randomly assigned to the experimental group (1.4 mg intralesional betamethasone) or to the control group (8 mg intralesional triamcinolone acetonide), and they received injections once a week for 2 weeks. Erosive area and pain level were assessed on days 1, 7 ± 2, and 14 ± 2. If the lesion disappeared, any recurrence within the following 3 months was recorded. Twenty-nine participants in the experimental group and 30 in the control group completed the protocol. Healed percentage was higher with betamethasone (93.1%) than with triamcinolone (66.7%; P = .02), and final reduction in erosion area was greater in the experimental group (21.276 ± 21.064 mm(2)) than in the control group (11.5 ± 12.95 mm(2); P = .02). Reduction in pain level did not differ between groups. The proportion of participants with recurrent erosions was significantly lower in the experimental group (14.8%) than in the control group (45%; P = .04). Intralesional betamethasone may be used in the topical treatment of erosive oral lichen planus.